Capital Advisors Ltd’s Forte Biosciences FBRX Stock Holding History

Capital Advisors Ltd’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14	Closed	–	–	1093
2022 Q1	$0	Buy	+14	New	+$530	﹤0.01%	997

Other funds holding FBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Advisors Ltd's FBRX Position: Q2 2022 in Review

Capital Advisors Ltd sold out of Forte Biosciences (FBRX) in Q2 2022, closing a stake of 14 shares.

Capital Advisors Ltd first reported a position in FBRX in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 39 funds tracked by Wall St. Rank hold FBRX as of Q2 2022.

Capital Advisors Ltd reported no remaining Forte Biosciences position as of Q2 2022 after selling out during the quarter.
Capital Advisors Ltd sold 14 Forte Biosciences shares in Q2 2022.
Capital Advisors Ltd first reported a position in Forte Biosciences in Q1 2022 and held it in 1 quarter.
Capital Advisors Ltd's Forte Biosciences position peaked at $0 in Q1 2022.
39 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2022.

Based on Capital Advisors Ltd's 13F filing for Q2 2022, filed 5 Aug 2022.